Teva links with Optimata for cancer research
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries will access novel technology for the virtual modelling of patient/drug interactions through an alliance with fellow Israeli company Optimata. The tie-up will focus on the reprofiling of molecules discontinued by originator companies for potential use in solid tumours. Optimata's virtual patient computer simulation technology allows the modelling of key human physiological processes to help determine optimum treatment, predict interactions and design clinical trials. Teva will make up-front, milestone and royalty payments and has also taken an undisclosed equity stake in Optimata as part of the deal.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.